TRAX
First Tracks Biotherapeutics, Inc. (TRAX) is rated C (2.3/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Momentum (B+); its weakest is Profitability (D-). The rating has held at C for 7 weeks.
Quantitative Factor Evaluation • Updated
Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms
Ratings of B- and above are for members.
Register free to see every rating — your first 2 weeks of Premium are on us.
Register — 2 weeks freeUnderlying Financial Metrics
Historical Factor Score Progression
| Date | Value | Growth | Profitability | Momentum | Revisions | Overall |
|---|---|---|---|---|---|---|
| 2026-11-15 | C+ (2.5) | C- (2.0) | D- (0.8) | B+ (3.7) | C+ (2.6) | C (2.3) |
| 2026-11-08 | C+ (2.5) | C- (2.0) | D- (0.8) | B (3.4) | C+ (2.6) | C (2.3) |
| 2026-11-01 | C+ (2.5) | C- (1.9) | D- (0.8) | B (3.3) | C+ (2.7) | C (2.3) |
| 2026-10-25 | C+ (2.5) | C- (1.9) | D- (0.8) | B+ (3.5) | C+ (2.6) | C (2.3) |
| 2026-10-18 | C+ (2.5) | C- (1.9) | D- (0.8) | B+ (3.6) | C+ (2.6) | C (2.3) |